x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to PCampbell@MJHLifesciences.com. Editor"s note: Episodes

health & fitness medicine

All Episodes

17:56

Tech Updates on Twiist, MiniMed Go, and More

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/01/16

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide an in-depth review of several notable developments in diabetes technology, focusing on innovations in insulin pump interoperability, automated insulin delivery algorithms, continuous glucose monitoring, and decision-support tools for people using multiple daily injections (MDI).Key Episode Timestamps00:00:01 Intro00:00:19 The

en-us

37:37

Reviewing the New US Dietary Guidelines with Susan...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2026/01/15

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, welcome Susan Weiner, MS, a nationally recognized dietitian and diabetes care and education specialist, for an in-depth discussion of the newly released US Dietary Guidelines and the inverted food pyramid. The conversation is framed for clinicians navigating nutrition counseling in diabetes and cardiometabolic care, with a focus on how

en-us

18:18

Therapeutic Updates from the ADA 2026 Standards of Care

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/24

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review key therapy-focused updates from the 2026 ADA Standards of Care, emphasizing areas they view as practice-changing. Key Episode Timestamps 00:00:01 Intro 00:00:29 Adding GLP-1 RAs to heart failure 00:02:45 GLP-1s in glycemic management 00:04:36 Time in range targets in glycemic management 00:08:10 ADA recommends GLP-1s for

en-us

18:45

Orforglipron, Cagrilintide, and the Libre Assist

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/23

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at the University Hospitals Diabetes and Metabolic Care Center, review major therapeutic and technology

en-us

27:35

2026 Technology Updates and American Diabetes...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/17

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, discuss major diabetes technology updates alongside key technology-related changes in the 2026 American Diabetes Association Standards of

en-us

9:41

Reacting to Retatrutide and TRIUMPH-4 Topline Data

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/12/17

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, share early impressions of topline phase 3 results from the TRIUMPH-4 trial of retatrutide, a once-weekly triple agonist targeting GIP, GLP-1,

en-us

13:25

Semaglutide Falls Short in Alzheimer Disease,...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/11/25

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, breakdown recent trial news from the 2 most popular incretin therapies: semaglutide and tirzepatide. First, hosts breakdown the November 24, 2025 announcement from Novo Nordisk disclosing their evoke and evoke+ trials of oral semaglutide in early symptomatic Alzheimer Disease failed to slow disease progression. Next, hosts break down the TIRTLE study, which examined use of tirzepatide in patients with type 1

en-us

20:49

Updates on Dexcom G7 and Semaglutide Pricing

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/11/21

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, review two major developments in diabetes care: the forthcoming 15-day Dexcom G7 continuous glucose monitor (CGM) and significant new price reductions for semaglutide as Ozempic and Wegovy.Key Episode Timestamps 00:00:01 Introduction 00:00:30 Dexcom G7 00:01:55 A 15-Day Sensor With a 12-Hour Grace Period 00:04:27 Seamless transition to the new G7 00:05:23 Looking back at Dexcom's advancements 00:06:34 Dexcom's Smart Basal

en-us

14:24

Oral Semaglutide and SELECT at DTM 2025

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/10/29

In this episode, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, meet in person at the Diabetes Technology Meeting (DTM) in San Francisco to discuss the latest clinical and regulatory advances surrounding semaglutide.Key Episode Timestamps 00:00:01 Introduction 00:00:42 Oral semaglutide's FDA approval 00:02:02 The SOUL trial and Rybelsus's cardiovascular indication 00:03:35 Dosing for Rybelsus 00:06:18 The SELECT trial 00:08:29 Can GLP-1s be cardiovascular treatments? 00:14:08 Outro

en-us

22:58

Biolinq Shine, Insulin Icodec, and Eli Lilly's Pipeline

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/10/14

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, explore 3 significant developments shaping diabetes care: a novel glucose-sensing technology, the return of once-weekly insulin icodec to the US Food and Drug Administration (FDA), and changes to Eli Lilly’s metabolic research pipeline. 00:00:01 Introduction 00:00:18 The Biolinq Shine 00:05:59 The Practicality of Monitoring

en-us

15:22

Celebrating 150 Episodes!

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/10/13

In this milestone 150th episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, reflect on three and a half years of transformation in diabetes care

en-us

36:01

What's New at Medtronic Diabetes With Bob Vigersky, MD

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/10/02

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down with Bob Vigersky, MD, Chief Medical Officer of Medtronic Diabetes, to discuss major developments in diabetes technology, regulatory approvals, and the company’s future direction. 00:00:00 Introduction 00:00:27 Background of Bob Vigersky, MD 00:02:40 Updates from Medtronic Diabetes 00:08:02 The Instinct Sensor 00:10:20

en-us

17:33

Results of ATTAIN-1 and STEP UP Phase 3 Trials

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/09/25

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospital Diabetes and Metabolic Care Center, discuss the recently published results of the ATTAIN-1 and STEP UP

en-us

17:35

Milestones for MiniMed 780G and Signos CGM for Weight...

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/09/07

In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, breakdown recent diabetes technology updates from late August and early September

en-us

13:33

Semaglutide & Tirzepatide Updates at ESC Congress 2025

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/09/05

At ESC 2025, a pair of presentations highlighted the ongoing debate over cardiovascular risk reduction with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), yielding conflicting signals that clinicians will need to interpret carefully. In this special edition episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie

en-us

13:17

FDA Approves Semaglutide (Wegovy) for MASH

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/08/22

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explore the latest milestone for semaglutide (Wegovy): US Food and

en-us

13:44

ADCES 2025 Part 3 & Diabetes Tech Updates

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/08/22

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, shared highlights on several major insulin delivery updates making waves at

en-us

21:29

ADCES 2025 Recap Part 2

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/08/22

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives! In this episode, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, highlight key advancements in diabetes management, particularly in

en-us

21:39

Orforglipron Topline Results & ADCES 2025 Part 1

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/08/19

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, share key insights and takeaways from the Association of Diabetes Care and Education Specialists (ADCES) 2025 annual meeting. 00:00:00 Introduction 00:00:25 Orforglipron and the ATTAIN-1 study 00:01:29 Why orforglipron is exciting 00:04:21 ADCES - Incredible Incretins 00:10:33 ADCES - AI in diabetes management 00:12:59 New AI tools for

en-us

11:13

Tirzepatide and SURPASS-CVOT Topline Results

Diabetes Dialogue: Technology, Therapeutics, &... ·

2025/08/05

On July 31, 2025, Eli Lilly and Company announced topline data from the SURPASS‑CVOT trial comparing tirzepatide (Mounjaro) to dulaglutide (Trulicity) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD).According to the data, tirzepatide met the primary non‑inferiority endpoint for 3-point major adverse cardiovascular events (MACE) (hazard ratio [HR], 0.92; 95.3% CI, 0.83 to 1.01), while also showing additional benefits in A1C, weight reduction, renal

en-us

178 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown